Calliditas' partner Everest gets review of kidney disease drug Nefecon in China

Nov. 15, 2022 5:00 AM ETCalliditas Therapeutics AB (publ) (CALT), CLTEFBy: Ravikash, SA News Editor

Medicine Concept

XtockImages/iStock via Getty Images

  • Calliditas Therapeutics (OTCPK:CLTEF) (NASDAQ:CALT) said China's National Medical Products Administration (NMPA) accepted to review Everest Medicines' new drug application (NDA) for kidney disease drug Nefecon.
  • Calliditas said that Nefecon, if approved, will be the first-ever approved therapeutic option

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.